Product Description
Sotrastaurin is an orally available pan-protein kinase C (PKC) inhibitor with potential immunosuppressive and antineoplastic activities. Sotrastaurin inhibits both T- and B-cell activations via PKC theta and beta isozymes, respectively.
Mechanisms of Action: PKC Theta Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Novartis
Company Location: BASEL V8 CH 4056
Company CEO: Vasant Narasimhan
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Renal Transplant|Kidney Transplant|Colitis, Ulcerative|Uveal Melanoma|Prolymphocytic Leukemia|Chronic Lymphoid Leukemia|Lymphoma, B-Cell|Lymphocytic Chronic B-Cell Leukemia|Prolymphocytic B-Cell Leukemia|Mantle-Cell Lymphoma|Panuveitis|Transplantation Unspecified|Uveitis, Posterior|Psoriasis|Liver Transplant|Kidney Diseases|Diffuse Large B-Cell Lymphoma|Arthritis, Psoriatic|Healthy Volunteers
Phase 1: Diffuse Large B-Cell Lymphoma|Healthy Volunteers|Uveal Melanoma|Liver Transplant
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| COEB071X2102 | P1 |
Completed |
Uveal Melanoma |
2019-05-22 |
41% |
| AAAN4901 | P1 |
Completed |
Uveal Melanoma |
2017-10-18 |
|
| 2013-001265-16 | P2 |
Terminated |
Diffuse Large B-Cell Lymphoma |
2016-06-01 |
|
| COEB071X2103 | P1 |
Completed |
Diffuse Large B-Cell Lymphoma |
2016-06-01 |
41% |